[Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
14 patients with primary, secondary or concurrent in situ carcinoma of the urinary bladder were treated intravesically with a solution of Bacillus Calmette-Guerin (BCG). Complete tumour remission was achieved in 9 patients. Local toxicity forced discontinuation of treatment in 3 patients. Tumour progression was not observed during treatment in any patient. Although there are still several unsolved questions concerning intravesical BCG treatment, it may already be considered to play an important role in organ-preserving bladder cancer therapy.
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine
Intravesikale Immuntherapie des In-situ-Karzinoms der Harnblase mit Bacillus-Calmette-Guerin (BCG).